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ABSTRACT Aspergillus fumigatus is the predominant pathogen of invasive aspergil-
losis, a disease state credited with over 200,000 life-threatening infections each year.
The triazole class of antifungals are clinically essential to the treatment of invasive
aspergillosis, both as frontline and as salvage therapy. Unfortunately, resistance to
the triazoles among A. fumigatus isolates is now increasingly reported worldwide,
and a large proportion of this resistance remains unexplained. In this work, we char-
acterize the contributions of previously identiﬁed mechanisms of triazole resistance,
including mutations in the sterol-demethylase-encoding gene cyp51A, overexpres-
sion of sterol-demethylase genes, and overexpression of the efﬂux pump-encoding
gene abcC, among a large collection of highly triazole-resistant clinical A. fumigatus
isolates. Upon revealing that these mechanisms alone cannot substantiate the
majority of triazole resistance exhibited by this collection, we subsequently describe
the identiﬁcation and characterization of a novel genetic determinant of triazole re-
sistance. Mutations in the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase-encoding gene, hmg1, were identiﬁed in a majority of triazole-resistant
clinical isolates in our collection. Introduction of three different hmg1 mutations,
predicted to encode residue alterations in the conserved sterol sensing domain of
Hmg1, resulted in signiﬁcantly increased resistance to the triazole class of agents.
Additionally, correction of a hmg1 mutation in a pan-triazole-resistant clinical isolate
of A. fumigatus with a novel Cas9-ribonucleoprotein-mediated system was shown to
restore clinical susceptibility to all triazole agents. Mutations in hmg1 were also
shown to lead to the accumulation of ergosterol precursors, such as eburicol, by ste-
rol proﬁling, while not altering the expression of sterol-demethylase genes.
IMPORTANCE Aspergillus fumigatus is the predominant pathogen of invasive asper-
gillosis, a disease state credited with over 200,000 life-threatening infections annu-
ally. The triazole class of antifungals are clinically essential to the treatment of inva-
sive aspergillosis. Unfortunately, resistance to the triazoles among A. fumigatus
isolates is now increasingly reported worldwide. In this work, we challenge the cur-
rent paradigm of clinical triazole resistance in A. fumigatus, by ﬁrst demonstrating
that previously characterized mechanisms of resistance have nominal impact on tria-
zole susceptibility and subsequently identifying a novel mechanism of resistance
with a profound impact on clinical triazole susceptibility. We demonstrate that muta-
tions in the HMG-CoA reductase gene, hmg1, are common among resistant clinical
isolates and that hmg1 mutations confer resistance to all clinically available triazole
antifungals.
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Aspergillus fumigatus is the predominant pathogen isolated from patients withinvasive aspergillosis, the most common human invasive mold infection. Invasive
aspergillosis is responsible for more than 200,000 life-threatening infections each year
and afﬂicts up to 10% of patients with acute leukemia as well as patients receiving stem
cell or solid organ transplantation (1–3). Unfortunately, the mortality rates associated
with invasive aspergillosis remain unacceptably high, often exceeding 50%, even when
appropriately diagnosed and treated (3–6).
Contributing to the poor outcomes associated with the treatment of invasive
aspergillosis is the relative paucity of clinically available antifungal agents with dem-
onstrated clinical efﬁcacy. Of the four major classes of antifungals, only the triazoles and
amphotericin B are recommended as monotherapy for the treatment of aspergillosis,
with the latter relegated to second-line or salvage treatment due to signiﬁcant toxicities
and the lack of oral formulations (7). The triazole class of antifungals therefore has
proven essential to the treatment of invasive aspergillosis, comprising both frontline
treatment options such as voriconazole and isavuconazole and salvage options such as
posaconazole and itraconazole (7). These agents are generally accepted to exert
fungicidal activity against Aspergillus through the competitive inhibition of sterol-
demethylase, encoded by the genes cyp51A (Afu4g06890) and cyp51B (Afu7g03740) in
A. fumigatus, which results in abrogation of the synthesis of ergosterol, the major fungal
membrane sterol (8–11). However, the treatment of invasive aspergillosis has recently
been further complicated by the global emergence of triazole-resistant disease. Over
the past decade, triazole resistance among clinical isolates of A. fumigatus has been
increasingly reported on six continents, with resistance rates exceeding 20% now being
reported in some studies (12–15).
Considerable research has led to the identiﬁcation of three distinct molecular
pathways to clinical triazole resistance in A. fumigatus. These three paths largely mirror
the established mechanisms of resistance previously identiﬁed in other pathogenic
fungi such as Candida albicans: (i) mutations in the sterol-demethylase gene cyp51A, (ii)
overexpression of the sterol-demethylase gene cyp51A, and (iii) overexpression of the
efﬂux pump-encoding gene abcC (16–25). However, it remains unknown to what extent
these mechanisms explain the degree of triazole resistance observed among clinical
isolates of A. fumigatus, and resistant clinical isolates exhibiting none of these three
mechanisms have been repeatedly identiﬁed (22). Thus, the molecular mechanisms
underpinning much of the clinical resistance to this essential class of anti-Aspergillus
agents remain unexplained, limiting the discovery of therapeutic strategies to over-
come triazole-resistant aspergillosis.
In this work, we perform a comprehensive characterization of the direct contribu-
tions of previously identiﬁed mechanisms of triazole resistance in a large collection of
triazole-resistant clinical isolates of A. fumigatus. We correct cyp51A mutations in 10
different triazole-resistant clinical isolates using a novel Cas9-mediated transforma-
tion system to delineate the direct impact these mutations have on clinical triazole
susceptibility, and we assess the potential impact of overexpression of cyp51A,
cyp51B, and abcC on triazole susceptibility in a collection of 21 triazole-resistant
clinical isolates. We subsequently demonstrate that these mechanisms alone fail to
explain the resistance observed in this collection. We further describe here, for the
ﬁrst time, a novel mechanism of clinical triazole resistance which was found to be
present in a majority of triazole-resistant clinical isolates in our collection. Mutations in
the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase-encoding gene,
hmg1 (Afu2g03700), were found to result in dramatically increased resistance to all
clinically available triazole agents. Additionally, the restoration of hmg1 to the wild-type
sequence in a clinical A. fumigatus isolate exhibiting high-level pan-triazole resistance
was found to restore clinical susceptibility to the triazole class. We demonstrate that
mutations in hmg1 result in sustained or even increased ergosterol production as well
as accumulation of multiple ergosterol precursors, including eburicol, the substrate of
the sterol-demethylase enzymes, which the triazole antifungals competitively inhibit.
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RESULTS
Mutations in sterol-demethylase alone poorly explain clinical triazole resis-
tance. Mutations in the sterol-demethylase gene cyp51A are the most frequently
identiﬁed mechanism of triazole resistance in A. fumigatus (6, 15, 26). We sought to
delineate the proportion of triazole resistance observed in individual clinical isolates
explained by this mechanism. To accomplish this, a collection of 26 clinical isolates of
A. fumigatus originating from the United States was obtained from the Fungus Testing
Laboratory at the University of Texas Health Science Center at San Antonio, including
21 multitriazole-resistant isolates with previously reported clinical origins and charac-
terized cyp51A genotypes and 5 triazole-susceptible control isolates (15). High-quality
genomic DNA was extracted from each of the 26 isolates, whole-genome sequencing
was performed targeting a read depth of approximately 100 reads per base aligned to
the Af293 A. fumigatus reference genome assembly, and a total of 48,552 SNPs and
insertions or deletions (indels) unique to triazole-resistant isolates were identiﬁed
within 8,669 genes with annotations available. Of the 21 triazole-resistant isolates in
this collection, 16 were identiﬁed as possessing peptide-sequence-altering cyp51A
mutations unique to resistant isolates. Conversely, no unique cyp51B mutations were
identiﬁed. We selected 10 of these 16 isolates with cyp51A mutations, which also
exhibited resistance to all clinically available triazole agents, for correction of the
cyp51A sequence to that of the wild-type consensus sequence. These isolates included
examples of previously characterized cyp51A mutations (TR34/L98H, TR46/Y121F/T289A,
and G448S), mutations at residues where alternative mutations have previously been
characterized (G138C and F219S), and mutations never before characterized to our
knowledge (M263I and I367F) (Table 1) (17, 24, 25, 27, 28).
In order to test the direct contribution of these mutations to clinical triazole
resistance in these isolates, the wild-type cyp51A promoter region and open reading
frame from the triazole-susceptible reference strain Af293 were ﬁrst cloned upstream of
the hygromycin resistance cassette in plasmid pCR-HygR (29). Fifteen hundred bases of
the cyp51A terminator was then cloned downstream of the hygromycin resistance
cassette, yielding the plasmid pCyp51A-HygR. Then, the cyp51AWT transformation repair
template was created by PCR using primers which ampliﬁed the wild-type cyp51A allele
(including 500 bases of promoter sequence), the hygromycin resistance cassette, and
TABLE 1 Triazole MICs of clinical isolates and derivative cyp51AWT strainsa
Parent clinical isolate or
derivative cyp51AWT strain cyp51A genotype
MIC (mg/liter) of triazole:
Voriconazole Itraconazole Posaconazole
DI15-117 F219S 2 >32 2
DI15-117 cyp51AWT WT 4 >32 4
DI15-100 M263I 8 >32 1
DI15-100 cyp51AWT WT 8 >32 0.5
DI15-116 TR34/L98H 8 >32 1
DI15-116 cyp51AWT WT 1 0.25 0.125
DI15-102 TR34/L98H 8 >32 2
DI15-102 cyp51AWT WT 4 >32 0.5
DI15-108 G138C 4 >32 1
DI15-108 cyp51AWT WT 4 >32 0.125
DI15-95 M263I 16 >32 2
DI15-95 cyp51AWT WT 16 >32 1
DI15-98 I367F 16 16 2
DI15-98 cyp51AWT WT 16 >32 1
DI15-96 TR46/Y121F/T289A >32 4 1
DI15-96 cyp51AWT WT >32 0.5 0.25
DI15-106 TR46/Y121F/T289A >32 4 1
DI15-106 cyp51AWT WT 8 2 0.5
DI15-120 G448S >32 >32 1
DI15-120 cyp51AWT WT >32 >32 1
aMICs shown in bold are greater than epidemiologic cutoff values as published by the Clinical Laboratory
and Standards Institute (1 mg/liter for voriconazole and itraconazole; 0.25 mg/liter for posaconazole). WT,
cyp51A sequence matches the Af293 wild-type consensus sequence.
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500 bases of the cyp51A terminator. Importantly, this repair template extends approx-
imately 200 bases upstream of the promoter region where characterized regulatory
elements and tandem repeat sequences have been identiﬁed (21). Protoplasts of each
of the 10 triazole-resistant clinical isolates, as well as the well-characterized triazole-
susceptible laboratory strain akuBKU80 (CEA17 akuBKU80), which has a wild-type cyp51A
allele, were then transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting
of Cas9 protein and CRISPR RNA (crRNA) and trans-activating CRISPR RNA (trRNA)
duplexes targeting sequences immediately upstream and downstream of the cyp51A
locus. The resulting transformants were selected on Aspergillus minimal medium con-
taining hygromycin as previously described (29, 30). Integration of the repair template
at the native cyp51A locus was conﬁrmed by PCR, and acquisition of the cyp51AWT
sequence was veriﬁed by Sanger sequencing.
Clinical susceptibility testing was performed for each of the 10 triazole-resistant
clinical isolates and the corresponding cyp51AWT derivative strains for voriconazole,
itraconazole, and posaconazole according to the Clinical and Laboratory Standards
Institute M38-A2 standards (Table 1) (31). All of the resistant clinical isolates exhibited
triazole MICs consistent with those previously reported for these isolates under clinical
susceptibility testing conditions, and all MICs for each agent tested were above
epidemiologic cutoff values previously reported by CLSI (1 mg/liter for voriconazole
and itraconazole and 0.25 mg/liter for posaconazole) (15, 32). Among the cyp51AWT
strains, only one strain (DI15-116 cyp51AWT) was observed to have full restoration of
wild-type triazole susceptibility, and two strains (DI15-96 cyp51AWT and DI15-108
cyp51AWT) were observed to have restoration of wild-type susceptibility to at least one
triazole. Additionally, two strains (DI15-102 cyp51AWT and DI15-106 cyp51AWT) were
observed to have at least one triazole MIC decrease by more than 1 dilution. Five of
the 10 cyp51AWT derivative strains exhibited no change in susceptibility to any triazole
agent tested. Importantly, replacement of the native wild-type cyp51A allele with the
cyp51AWT cassette in the akuBKU80 background had no effect on triazole MIC. Taken
together, these data demonstrate that while mutations in cyp51A are common among
triazole-resistant clinical isolates of A. fumigatus, and a number of these mutations have
been demonstrated to increase triazole MICs when introduced into a triazole-
susceptible background, mutations in cyp51A alone poorly explain the high level of
triazole resistance observed in this collection of clinical isolates.
Analysis of the expression of the sterol-demethylase genes cyp51A and cyp51B
among triazole-resistant clinical isolates. Triazole-resistant clinical isolates of A.
fumigatus exhibiting overexpression of cyp51A and cyp51B, relative to susceptible
comparator isolates, have previously been reported (22, 33, 34). Additionally, both the
formation of tandem repeats (TR34, TR46, and TR53) in the promoter region of cyp51A
and a mutation (encoding the amino acid substitution P88L) in hapE, a CCAAT-binding
complex protein-encoding gene which participates in the negative regulation cyp51A
expression, have been shown to increase both cyp51A expression and triazole MICs (20,
21, 24, 25). Following the observation that mutations in cyp51A alone do not explain the
degree of triazole resistance observed in this collection of clinical isolates, we sought to
evaluate the potential contributions of sterol-demethylase gene overexpression to
clinical triazole resistance. To accomplish this, each of the 26 clinical isolates in our
collection was grown overnight at 37°C in Aspergillus minimal medium in biological
triplicate, and RNA was extracted from mature hyphae following liquid nitrogen crush
as previously described (35). Reverse transcription-quantitative-PCR (RT-qPCR) was then
utilized to quantify the relative expression of both cyp51A and cyp51B in each of the 21
triazole-resistant clinical isolates compared to the expression level observed among the
5 triazole-susceptible control isolates.
The expression of cyp51A and cyp51B in all clinical isolates was compared to the
triazole-susceptible isolate DI16-6 (voriconazole MIC, 0.5 mg/liter). Among triazole-
susceptible control isolates, the expression of cyp51A ranged from 0.5- to 1.6-fold that
of isolate DI16-6 (Fig. 1a), with isolates DI16-5, DI16-7, and DI16-9 exhibiting statistically
signiﬁcant lower expression of cyp51A. The expression of cyp51A among triazole-
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resistant clinical isolates ranged from 0.7- to 3.5-fold that of the susceptible comparator
isolate. Twelve of the 21 triazole-resistant isolates were observed to have cyp51A
expression that exceeded the highest expression level observed among triazole-
susceptible isolates. Of these 12 isolates, 8 were found to have cyp51A expression levels
statistically greater than the susceptible comparator isolate. This included 2 isolates
(DI15-102 and DI15-116) which possess the TR34/L98H cyp51A mutation, 2 isolates
(DI15-96 and DI15-106) which possess the TR46/Y121F/T289A cyp51Amutation, and one
isolate (DI15-105) which possesses the previously characterized P88L-encoding muta-
tion in hapE. However, no previously characterized mutations known to contribute to
cyp51A overexpression were identiﬁed in the remaining 3 isolates. The expression of
cyp51B among the triazole-susceptible control isolates ranged from 0.7- to 1.3-fold that
FIG 1 Relative expression of cyp51A and cyp51B among triazole-resistant clinical isolates. (a) Expression of cyp51A
in clinical isolates relative to triazole-susceptible isolate DI16-6; identiﬁed mutations known to contribute to cyp51A
overexpression are shown on the corresponding bar. (b) Expression of cyp51B in clinical isolates relative to
triazole-susceptible isolate DI16-6; triazole-susceptible isolates are shown as open bars, and triazole-resistant
isolates are shown as ﬁlled bars. Triazole-resistant isolates shown in order of escalating voriconazole MICs from left
to right. Horizontal dotted lines denote highest and lowest expression levels observed among the 5 triazole-
susceptible isolates. Comparisons with the susceptible control isolate DI16-6 with statistically signiﬁcant (P  0.05)
results are noted with an asterisk.
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of isolate DI16-6 (Fig. 1b), with isolate DI16-8 exhibing statistically greater expression of
cyp51B (1.3-fold). The expression of cyp51B among triazole-resistant clinical isolates
ranged from 0.7- to 2.1-fold that of the susceptible comparator isolate, with 4 isolates
(DI15-95, DI15-97, DI15-102, and DI15-108) exhibiting expression of cyp51B exceeding
that of the highest expression level observed among triazole-susceptible isolates, 3 of
which (DI15-95, DI15-102, and DI15-108) were statistically signiﬁcant.
Constitutive overexpression of cyp51B decreases triazole susceptibility. Over-
expression of cyp51A has previously been shown to contribute to triazole resistance,
but it remains unknown if overexpression of the paralogous gene, cyp51B, has a similar
effect on triazole susceptibility. We sought to employ a novel Cas9-RNP mediated
promoter replacement system to delineate the direct impact of constitutive overex-
pression of cyp51B on triazole MIC. To accomplish this, the previously characterized,
strong, constitutive promoter from the heat shock protein-encoding gene, hspA
(Afu1g07440), was cloned upstream of the hygromycin resistance cassette in the
plasmid pCR-HygR (36). A transformation repair template for the cyp51B promoter
replacement was then constructed by amplifying the hspA promoter and hygromycin
resistance cassette from the resulting plasmid (pJMR2) with primers that introduced
approximately 50 bases of homology for the 3= end of the native promoter region and
the 5= end of the cyp51B open reading frame. Protoplasts of the well-characterized
triazole-susceptible laboratory strain akuBKU80 were then transformed with Cas9-
ribonucleoprotein (RNP) complexes, consisting of Cas9 protein and crRNA-trRNA du-
plexes targeting sequences immediately upstream of the cyp51B start codon, yielding
the strain akuBKU80_PhspAcyp51B (Fig. 2) (37). As a comparator, the same methodology
was employed to create the constitutive cyp51A-overexpressing strain akuBKU80_
PhspAcyp51A.
FIG 2 Schematic of Cas9-RNP-mediated promoter replacement system. Constitutive overexpression repair templates were ampliﬁed from
pJMR2 using primers incorporating microhomology targeting genes of interest (GOI) and then mixed with Cas9-RNP targeting immedi-
ately upstream of the start codon of the GOI, and protoplasts were created from the strain akuBKU80.
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The relative expression of both cyp51A and cyp51B in the strains akuBKU80_
PhspAcyp51A and akuBKU80_PhspAcyp51B was then compared to the parental akuBKU80
strain both under normal growth conditions and following voriconazole treatment.
Conidia from each strain were grown in Aspergillus minimal medium at 37°C until
germination and then were transferred to fresh Aspergillus minimal medium containing
either no voriconazole or 0.125 mg/liter of voriconazole (half of the MIC of the parental
akuBKU80 strain) for an additional 6 h at 37°C. RNA was extracted from each sample as
previously described, and RT-qPCR was performed. The expression of cyp51B in
akuBKU80 was 2-fold higher after treatment with voriconazole than under untreated
conditions (Fig. 3a). Expression of cyp51B in the akuBKU80_PhspAcyp51B strain was
35.9-fold higher under untreated conditions and 36.9-fold higher following voricona-
zole exposure than the expression measured in the parental akuBKU80 under untreated
FIG 3 Relative expression of cyp51A and cyp51B and voriconazole MICs in promoter replacement strains akuBKU80_PhspAcyp51A and
akuBKU80_PhspAcyp51B. (a) The expression of cyp51A (left) and cyp51B (right) in akuBKU80, akuBKU80_PhspAcyp51A, and akuBKU80_PhspAcyp51B was
determined by RT-qPCR following growth in Aspergillus minimal medium at 37°C both with voriconazole (0.125 mg/liter) treatment for 6 h and
without voriconazole treatment. The expression level for each sample is shown relative to that of the respective gene in akuBKU80 without
voriconazole treatment. (b) Voriconazole MICs for akuBKU80, akuBKU80_PhspAcyp51A, and akuBKU80_PhspAcyp51B. Comparisons with statistically
signiﬁcant (P  0.05) results are noted with an asterisk, while those that are not are noted with “ns.”
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conditions. This increased expression was statistically greater than in the parental strain
under both treated and untreated conditions. The expression of cyp51B in the
akuBKU80_PhspAcyp51A strain approximated that of akuBKU80 under both untreated and
voriconazole-treated conditions. The expression of cyp51A in akuBKU80 was 4.1-fold
higher following treatment with voriconazole than under untreated conditions. Expres-
sion of cyp51A in the akuBKU80_PhspAcyp51A strain was 14.1-fold higher under untreated
conditions, and 18.5-fold higher following voriconazole exposure, than the expression
measured in the parental akuBKU80 under untreated conditions. This increased expres-
sion was statistically greater than in the parental strain under both treated and
untreated conditions. The expression of cyp51A in the akuBKU80_PhspAcyp51B strain was
similar to that of akuBKU80 under both untreated and voriconazole-treated conditions.
Upon conﬁrmation of the constitutive overexpression of cyp51A and cyp51B in the
akuBKU80_PhspAcyp51A and akuBKU80_PhspAcyp51B strains, respectively, voriconazole
MICs were determined in triplicate according to CLSI M38-A2 standards (31). The
parental akuBKU80 strain exhibited a voriconazole MIC of 0.25 mg/liter. The akuBKU80_
PhspAcyp51A strain was observed to have a 2-fold increase in voriconazole MIC (0.5
mg/liter), which is similar to the decrease in susceptibility previously reported when
expression of this gene is increased as a result of either the formation of tandem
repeats in the cyp51A promoter or a mutation in hapE (Fig. 3b) (20, 21, 24, 25).
Interestingly, the voriconazole MIC of the akuBKU80_PhspAcyp51B strain was 1 mg/liter,
4-fold higher than the parental isolate. Taken together, these results demonstrate that
overexpression of either sterol-demethylase gene can decrease triazole susceptibility.
However, even when the expression of either of these genes increased by as much as
36.9-fold, the MIC did not exceed the epidemiological cutoff value for voriconazole
reported by CLSI (1 mg/liter) (32).
Analysis of the expression of the efﬂux pump-encoding gene abcC among
triazole-resistant clinical isolates. In addition to sterol-demethylase-mediated mech-
anisms of triazole resistance, increased constitutive expression of the ATP-binding
cassette efﬂux pump-encoding gene, abcC (Afu1g14330; also known as abcB, cdr1B, and
abcG1), has been associated with triazole resistance in A. fumigatus (22, 23, 38).
Furthermore, deletion of abcC in both triazole-susceptible laboratory strains of A.
fumigatus and a triazole-resistant clinical isolate has been shown to increase triazole
susceptibility (22, 23, 38). As cyp51A- and cyp51B-mediated mechanisms alone do not
adequately explain the high level of triazole resistance in this collection of clinical
isolates, we sought to characterize the expression of abcC and its potential impact on
triazole susceptibility. To accomplish this, each of the 26 clinical isolates in our collec-
tion was grown overnight at 37°C in Aspergillusminimal medium in biological triplicate,
and RNA was extracted as previously described. RT-qPCR was then utilized to quantify
the relative expression of abcC in each of the 21 triazole-resistant clinical isolates
compared to the expression level observed among the 5 triazole-susceptible control
isolates.
The expression of abcC in all clinical isolates was compared to the triazole-
susceptible isolate DI16-6. Among triazole-susceptible control isolates, the expression
of abcC ranged from 0.7- to 2-fold that of isolate DI16-6 (Fig. 4a), with both isolates
DI16-5 and DI16-8 exhibiting statistically greater abcC expression (1.3- and 2.0-fold,
respectively) than DI16-6. The expression of abcC among triazole-resistant clinical
isolates ranged from 1.2- to 33.2-fold that of the susceptible comparator isolate.
Nineteen of the 21 triazole-resistant isolates were observed to have abcC expression
that was statistically greater than the expression observed in the susceptible control
isolate DI16-6, 14 of which exhibited abcC expression which also exceeded the highest
expression level observed among triazole-susceptible isolates (2-fold). While the ma-
jority of these 14 isolates exhibited modestly elevated abcC expression (2.4- to 4.1-fold
that of the comparator susceptible isolate), isolates DI15-110, DI15-120, and DI15-106
exhibited markedly higher levels of abcC expression (6.5-, 10.4-, and 33.2-fold, respec-
tively). Notably, the pan-triazole-resistant isolate DI15-110, which exhibited the highest
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level of abcC expression, possesses no mutations in cyp51A and did not exhibit
increased constitutive expression of either sterol-demethylase gene.
As previous studies associating increased triazole resistance with abcC have entirely
relied upon deletion of the abcC gene among either clinical or laboratory isolates of A.
fumigatus, we next sought to utilize our Cas9-RNP-mediated promoter replacement
system to delineate the direct impact of constitutive overexpression of abcC on triazole
MIC. To accomplish this, protoplasts of the triazole-susceptible laboratory strain
akuBKU80 were transformed with Cas9-ribonucleoprotein (RNP) complexes, consisting of
Cas9 protein and crRNA-trRNA duplexes targeting sequences immediately upstream of
the abcC start codon, as well as the PhspAabcC transformation repair template, which
contains both the hspA promoter and hygromycin resistance cassette ﬂanked by 50
bases of microhomology targeting the abcC locus, yielding the strain akuBKU80_
PhspAabcC. Subsequently, the relative expression of abcC in both akuBKU80_PhspAabcC
FIG 4 Relative expression of abcC in triazole-resistant clinical isolates and the constitutive overexpression strain
akuBKU80_PhspAabcC. Triazole-susceptible isolates are shown as open bars; triazole-resistant isolates are shown as ﬁlled bars.
Triazole-resistant isolates shown in order of escalating voriconazole MICs from left to right. Horizontal dotted lines denote
highest and lowest expression levels observed among the 5 triazole-susceptible isolates. (a) Expression of abcC relative to
triazole-susceptible isolate DI16-6. (b) The expression of abcC in strains akuBKU80 and akuBKU80_PhspAabcC was determined
by RT-qPCR following growth in Aspergillus minimal medium at 37°C both with voriconazole (0.125 mg/liter) treatment for
6 h and without voriconazole treatment. The expression level for each sample is shown relative to that of the respective
gene in akuBKU80 without voriconazole treatment. Comparisons with statistically signiﬁcant (P  0.05) results are noted
with an asterisk, while those that are not are noted with “ns.”
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and the parental strain akuBKU80 was assessed by RT-qPCR following growth in Asper-
gillus minimal medium at 37°C both with voriconazole treatment (0.125 mg/liter) for 6
h and without.
In the parental akuBKU80 strain, abcC expression was signiﬁcantly (9.7-fold) higher
following voriconazole treatment than was observed without voriconazole treatment
(Fig. 4b). By comparison, the akuBKU80_PhspAabcC strain exhibited 7.8-fold- and 10.4-
fold-higher abcC expression, under untreated and voriconazole-treated conditions,
respectively, than the expression of abcC measured in the parental akuBKU80 under
untreated conditions. abcC expression was not found to be signiﬁcantly different
between akuBKU80_PhspAabcC and the parental strain when both had been treated with
voriconazole for 6 h. Surprisingly, even with an approximately 10-fold increase in the
constitutive expression of abcC, the akuBKU80_PhspAabcC strain did not demonstrate any
change in voriconazole susceptibility relative to the parental akuBKU80 strain (MIC, 0.25
mg/liter).
Mutations in hmg1 are common among triazole-resistant clinical isolates of A.
fumigatus. Following the ﬁnding that the previously characterized mechanisms of
triazole resistance did not explain the high level of triazole resistance observed in this
collection of clinical A. fumigatus isolates, we sought to interrogate the previously
generated whole-genome sequencing data to identify novel mechanisms of resistance.
As the triazoles exert antifungal activity through the inhibition of biosynthesis of
the predominant fungal membrane sterol ergosterol, initial whole-genome se-
quencing analysis targeted genes encoding proteins known to participate in ergos-
terol biosynthesis. In addition to the previously identiﬁed cyp51A mutations, mutations
unique to triazole-resistant isolates were also observed in erg3B (Afu2g00320), erg3C
(Afu8g01070), erg4B (Afu1g07140), erg5 (Afu1g03950), and erg6 (Afu4g03630). How-
ever, mutations occurred in these genes among only a small number of the clinical
isolates (see Table S1 in the supplemental material). Intriguingly, 11 of the 21 triazole-
resistant clinical isolates (52%) were found to possess mutations in the hmg1 gene
resulting in peptide sequence changes not observed among the triazole-susceptible
control isolates (Fig. 5a). The A. fumigatus hmg1 gene encodes a HMG-CoA reductase
enzyme previously reported to be essential. HMG-CoA reductase catalyzes the ﬁrst
committed step in ergosterol biosynthesis and has previously been shown in other
eukaryotic organisms to participate in the regulation of sterol biosynthesis through
direct interactions between sterols and a conserved sterol-sensing domain (39–42). Of
particular interest, eight of the 11 isolates with hmg1 mutations were found to have
mutations affecting residues predicted to reside within the conserved sterol-sensing
domain of Hmg1 (Fig. 5b). We additionally accessed publicly available whole-genome
sequencing data for 11 triazole-resistant clinical isolates (https://www.ebi.ac.uk/
arrayexpress/experiments/E-SYBR-1/samples/) and found 5 to have mutations in hmg1,
2 of which alter residues in the predicted sterol-sensing domain (P309L and I412T). As
mutations in hmg1 were observed in a large proportion of clinical triazole-resistant
isolates, and hmg1mutations have previously been observed among laboratory isolates
of A. fumigatus grown in the presence of triazole antifungals and the closely related
agricultural sterol-demethylase inhibitors, the observed mutations in hmg1 were se-
lected for further interrogation (43, 44).
Mutations in hmg1 confer resistance to the triazole class of antifungals. To test
the hypothesis that mutations in hmg1 directly contribute to clinical triazole resistance
in A. fumigatus, three mutations encoding amino acid substitutions or in-frame codon
deletions in different transmembrane regions of the predicted hmg1 sterol-sensing
domain (F262del, S305P, and I412S) were selected for characterization (Fig. 5b). Each of
these mutations and a wild-type control allele were directly introduced to the native
hmg1 locus of the triazole-susceptible laboratory strain akuBKU80 using a novel Cas9-
RNP editing technique incorporating a split hygromycin B resistance marker (Fig. S1).
Brieﬂy, hmg1 alleles including the open reading frame and approximately 500 down-
stream bases were ampliﬁed by PCR from DI15-98 (S305P), DI15-100 (I412S), DI15-105
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(F262del), and akuBKU80 (wild-type control) using a 3= primer which introduced the
terminal 80 bases with homology to the 3= end of the hphR hygromycin B resistance
gene open reading frame. A partial hygromycin B resistance cassette, including the
gdpA promoter and a truncated hphR gene lacking the terminal 40 bases, was then
ampliﬁed by PCR from the pUCGH plasmid using primers that introduced approxi-
mately 70 bases of homology with the downstream region of hmg1 (45). Protoplasts of
akuBKU80 were then transformed with RNP complexes, consisting of Cas9 protein and
crRNA-trRNA duplexes targeting sequences immediately upstream and approximately
500 bases downstream of the open reading frame of hmg1, and 2 g of each portion
of the split marker repair template (a single hmg1 allele and the truncated hygromycin
B resistance cassette), to produce hmg1 mutant strains akuBKU80 hmg1F262del, akuBKU80
hmg1S305P, akuBKU80 hmg1I412S, and akuBKU80 hmg1WT.
FIG 5 Mutations in hmg1 observed in this collection of triazole-resistant clinical A. fumigatus isolates. (a) hmg1 mutations observed in each clinical isolate
relative to the Af293 reference genome, with mutations affecting residues predicted to reside within the conserved sterol-sensing domain shown in bold. (b)
Schematic depicting the predicted transmembrane domains of A. fumigatus Hmg1. Residues in light blue comprise the predicted sterol-sensing domain,
residues in dark blue represent those affected by hmg1 mutations observed in this collection of clinical isolates, and residues shown in green represent those
affected by hmg1 mutations observed in this collection of clinical isolates and further characterized in this work.
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Antifungal susceptibility testing was subsequently performed for akuBKU80 and each
of the derivative strains for voriconazole, isavuconazole, itraconazole, posaconazole,
and amphotericin B according to the Clinical and Laboratory Standards Institute
M38-A2 standards (Fig. 6a) (31). The parental akuBKU80 strain was susceptible to all
agents with MICs of 0.25, 0.5, 0.125, 0.06, and 0.5 mg/liter for voriconazole, isavucona-
zole, itraconazole, posaconazole, and amphotericin B, respectively. The akuBKU80
hmg1WT control strain exhibited MICs exactly matching those of the parental strain.
Conversely, all strains harboring a clinically derived mutation in hmg1 were found to
exhibit a 4- to 8-fold increase in MICs for all tested triazoles, exceeding the CLSI
reported epidemiologic cutoff values for at least one agent in each mutant strain.
Notably, amphotericin B MICs were observed to decrease by 2-fold in both the akuBKU80
hmg1S305P and akuBKU80 hmg1F262del strains (0.5 versus 0.25 mg/liter) but not in
akuBKU80 hmg1I412S.
In an effort to delineate the extent of hmg1 mutation-mediated triazole resistance
within a clinical isolate from our collection, the mutant hmg1 allele in the pan-triazole-
resistant clinical isolate DI15-105 was replaced with the wild-type hmg1 allele from
akuBKU80 using the same Cas9-RNP-mediated gene editing described above. The
resultant DI15-105 hmg1WT strain exhibited complete restoration of triazole suscepti-
bility with an 8-fold or greater decrease in MIC for each triazole agent (Fig. 6b).
Intriguingly, the amphotericin B MIC was observed to increase by 2-fold in DI15-105
hmg1WT relative to DI15-105 (0.125 versus 0.25 mg/liter).
Mutations in hmg1 lead to accumulation of ergosterol precursors. As the
sterol-sensing domain of HMG-CoA reductase has previously been shown to interact
with ergosterol precursors and participate in the negative regulation of HMG-CoA
reductase activity in both human cells and the model ﬁssion yeast Schizosaccharomyces
pombe, we hypothesized that the mutations identiﬁed in the sterol-sensing domain of
A. fumigatus hmg1 may be leading to dysregulation of the ergosterol biosynthesis
pathway resulting in the observed triazole resistance (Fig. 7a) (39–42). To test this
hypothesis, comprehensive sterol proﬁling including assessment of the relative distri-
bution of cell sterols and the measurement of total ergosterol content per dry weight
FIG 6 Impact of hmg1 mutations on antifungal susceptibility. (a) Triazole MICs for akuBKU80 and derivative mutant hmg1 strains. (b) Triazole MICs for DI15-105
and derivative hmg1WT strain.
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was performed on akuBKU80, akuBKU80 hmg1F262del, akuBKU80 hmg1S305P, akuBKU80
hmg1I412S, and akuBKU80 hmg1WT.
To assess the relative distribution of sterols among A. fumigatus strains harboring
hmg1 mutations, freshly harvested conidial stocks of each strain were grown in six
biological replicates in RPMI medium supplemented with 0.2% glucose and buffered
with MOPS (pH 7.0) for 24 h before cells were ﬂash frozen with liquid nitrogen, dry
weights were obtained, and nonsaponiﬁable lipids were extracted, derivatized, and
analyzed by gas chromatography-mass spectrometry as described previously (46, 47).
In agreement with the hypothesis that mutations in hmg1 precipitate dysregulation
of the ergosterol biosynthetic pathway, the distribution of sterols was dramatically
altered in all hmg1 mutant strains relative to akuBKU80 (Fig. 7b). Most notably, a
signiﬁcant decrease in the relative proportion of ergosterol, along with corresponding
increases in the proportions of several ergosterol precursors downstream of Hmg1,
FIG 7 Relative distribution of sterols and total ergosterol content of hmg1 mutant strains. (a) A. fumigatus ergosterol biosynthetic
pathway. (b) Relative fold change of cellular sterols lanosterol, eburicol, 4,4-dimethylergosta-8,24(28)-dienol, fecosterol, episterol, and
ergosterol in hmg1 mutant strains compared to the parental akuBKU80 strain. (c) Total cellular ergosterol per dry weight for hmg1
mutant strains and the parental akuBKU80 strain. Comparisons with the susceptible parental isolate akuBKU80 with statistically signiﬁcant
(P  0.05) results are noted with an asterisk.
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including eburicol, 4,4-dimethylergosta-8,24(28)-dienol, and fecosterol, were observed
in all mutant hmg1 strains. Additionally, the relative proportion of episterol was
observed to be signiﬁcantly elevated in akuBKU80 hmg1F262del and akuBKU80 hmg1S305P.
Importantly, no signiﬁcant difference in the relative distribution of sterols was observed
between akuBKU80 and akuBKU80 hmg1WT (data not shown).
While the distribution of cellular sterols among A. fumigatus strains harboring hmg1
mutations demonstrated a signiﬁcant decrease in the relative proportion of cellular
ergosterol, total ergosterol content per dry weight was not lower among any of the
mutant hmg1 strains (Fig. 7c). In fact, relative to the parental akuBKU80, akuBKU80
hmg1F262del was observed to exhibit a signiﬁcant increase in total ergosterol (4.56
versus 7.06 g ergosterol/mg [dry weight]; P  0.01). Taken together, these ﬁndings
demonstrate hmg1 mutations precipitate a relative increase in ergosterol precursors
downstream of Hmg1, while maintaining or in some cases even increasing cellular
ergosterol, leading to signiﬁcantly altered cellular sterol proﬁles among mutant hmg1
strains.
Mutations in hmg1 do not lead to increased expression of sterol-demethylase
genes. As our sterol proﬁling studies revealed signiﬁcant accumulations of ergosterol
precursors both upstream and downstream of sterol-demethylase, and we had previ-
ously observed that increased expression of either sterol-demethylase gene contributes
to triazole resistance, we sought to investigate if the triazole resistance associated with
mutations in hmg1 was at least in part mediated by altered expression of sterol-
demethylase genes. To accomplish this, conidial suspensions of akuBKU80, akuBKU80
hmg1F262del, akuBKU80 hmg1S305P, akuBKU80 hmg1I412S, and akuBKU80 hmg1WT were
grown in biological triplicates under the same conditions used for sterol proﬁle analysis,
and RNA was extracted from liquid nitrogen-pulverized samples, as previously de-
scribed (35). RT-qPCR was then performed to assess expression of the sterol-
demethylase genes cyp51A and cyp51B among mutant hmg1 strains relative to the
parental akuBKU80. No signiﬁcant differences in expression of either sterol-demethylase
gene were observed for any of the mutant hmg1 strains or the akuBKU80 hmg1WT
control strain (Fig. 8). This ﬁnding demonstrated that while mutant hmg1 strains are
observed to have relatively greater proportions of ergosterol precursors, expression
levels of both cyp51A and cyp51B remain unchanged. Thus, resistance in these strains
is not due to increased expression of these genes.
DISCUSSION
Resistance to the triazole class of antifungals represents a critical threat to the
current treatment of invasive aspergillosis, a devastating disease state primarily afﬂict-
FIG 8 Expression of sterol-demethylase genes is not elevated among mutant hmg1 strains. Fold
expression of cyp51A and cyp51B in mutant hmg1 strains relative to the parental akuBKU80 strain as
determined by reverse transcription-quantitative PCR.
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ing the expanding populations of immunocompromised patients worldwide. While
considerable research has been performed to interrogate the mechanisms by which
pathogenic fungi such as Aspergillus become resistant to triazole antifungals, the
overwhelming majority of resistance has been ascribed to three canonical paths that
were originally described among pathogenic fungi decades ago: mutations in sterol-
demethylase genes, overexpression of sterol-demethylase, or overexpression of efﬂux
pump-encoding genes. However, these mechanisms alone or even in combination
poorly explain a large proportion of the triazole resistance observed among clinical A.
fumigatus isolates today.
In this work, we performed a comprehensive characterization of the direct contri-
butions of previously identiﬁed mechanisms of triazole resistance in a collection of
triazole-resistant clinical isolates of A. fumigatus. We observed that correction of cyp51A
mutations in 10 pan-triazole-resistant clinical isolates restored wild-type susceptibility,
to even a single triazole agent, in only 3 isolates. We then demonstrated that while
constitutive overexpression of cyp51A, and to a lesser extent cyp51B, was common
among isolates in this collection, increasing expression of either sterol-demethylase
gene by as much as 18- to 36-fold in the triazole-susceptible akuBKU80 background had
a limited effect on triazole MICs. Analogously, we then observed that while the
expression of the ABC-type efﬂux pump-encoding gene abcC was higher among 14 of
the triazole-resistant isolates in this collection, constitutive overexpression of this gene
in the akuBKU80 background did not have any effect on voriconazole MIC. Upon
revealing that the previously known mechanisms of clinical triazole resistance explain
only a small fraction of the resistance observed in this collection, we then utilized
whole-genome sequencing to identify a previously uncharacterized mechanism of
resistance present among the majority of the isolates.
Here, we describe for the ﬁrst time a novel and noncanonical mechanism of triazole
antifungal resistance. Identiﬁed through whole-genome sequencing, mutations in the
HMG-CoA reductase-encoding gene, hmg1, were found among the majority of triazole-
resistant A. fumigatus clinical isolates in our collection. Of the observed mutations, most
occurred in the conserved sterol-sensing domain of hmg1, which has been previously
demonstrated to participate in the regulation of sterol biosynthesis in other eukaryotic
organisms, including S. pombe. When three of these clinically derived hmg1 mutations
were independently introduced into a well-characterized triazole-susceptible strain of
A. fumigatus using an optimized Cas9-mediated system to replace the native hmg1
locus, resistance to all clinically available anti-Aspergillus triazole antifungals greatly
increased. To conﬁrm that mutations in hmg1 are a novel mechanism of clinical triazole
resistance, we employed the same system to correct a hmg1 mutation identiﬁed in a
pan-triazole-resistant clinical isolate of A. fumigatus and observed restoration of sus-
ceptibility to all triazoles.
As the sterol-sensing domain of HMG-CoA reductase has been shown to be essential
to the regulation of sterol biosynthesis, we hypothesized that amino acid substitutions
in this domain of Hmg1 may lead to impaired negative regulation of Hmg1 activity. In
an effort to test this hypothesis, we performed comprehensive sterol proﬁling on the
mutant hmg1 strains. This analysis identiﬁed signiﬁcant accumulations of ergosterol
precursors, including eburicol, 4,4-dimethylergosta-8,24(28)-dienol, fecosterol, and
episterol, while total cellular ergosterol content was seen to be sustained or, in the case
of the hmg1F262del mutation, signiﬁcantly increased. However, this increase in ergos-
terol precursors did not result in a subsequent increase in sterol-demethylase expres-
sion levels in any of the mutant hmg1 strains. Thus, hmg1 mutation-mediated triazole
resistance is not the result of increased sterol-demethylase gene expression.
Taken together, the results of this study identify mutations in the A. fumigatus
HMG-CoA reductase gene, hmg1, as a novel and noncanonical genetic determinant of
clinical triazole resistance, present among a large proportion of resistant clinical iso-
lates. While the exact mechanism by which mutations in the sterol-sensing domain of
hmg1 impart clinical triazole resistance remains unknown at this time, it is tempting to
speculate that the negative regulation of Hmg1 activity, which has been shown to be
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dependent on the sterol-sensing domain in other eukaryotic organisms, may be altered
by residue substitutions in the sterol-sensing domain of A. fumigatus Hmg1.
MATERIALS AND METHODS
Isolates, media, and growth conditions used in this study. Twenty-one previously characterized
multitriazole-resistant clinical isolates of A. fumigatus, and ﬁve triazole-susceptible control clinical isolates
of A. fumigatus, originating from the United States were obtained from the Fungus Testing Laboratory
at the University of Texas in San Antonio. The laboratory strains akuBKU80 and Af293 were obtained from
the Fungal Genetics Stock Center. All strains and clinical isolates used in this study were maintained on
glucose minimal medium (GMM) agar at 37°C. Transformants were selected for using sorbitol (1.2
M)-supplemented GMM agar (SMM) containing 150 mg/liter of hygromycin. All conidia were harvested
in sterile water from 3-day-old growth plates, and conidia were enumerated visually using a hemocy-
tometer.
Whole-genome sequencing. For each isolate, genomic DNA was extracted using the Qiagen DNeasy
Plant minikit as previously described (29). DNA concentrations were quantiﬁed using both the Qubit
ﬂuorometer and the NanoDrop spectrophotometer using the manufacturers’ protocols. Whole-genome
libraries were prepared and sequenced at the University of Tennessee Health Science Center Molecular
Resource Center. Bioinformatics services were provided by code4DNA. Sequence reads for each sample
were aligned using the STAR sequence alignment tool (v2.5.0b) to the A. fumigatus reference sequence
(version A_fumigatus_Af293_version_s03-m05-r05) which was downloaded from http://aspgd.org/. Du-
plicate alignments were marked using Picard (v1.119), and variants were called using Freebayes (v1.1.0)
using the haploid population-based model. The Freebayes output vcf ﬁle was split into individual sample
vcf ﬁles using bcftools (v1.3), and variants for each sample were annotated with snpEff (v4.2) using the
A. fumigatus reference sequence annotations. Visualization of Hmg1 peptide sequence was performed
using Protter (49).
Construction of promoter replacement repair templates and Cas9-RNP for cyp51A, cyp51B, and
abcC. The plasmid pJMR2 was constructed by cloning the proximal 1 kb of the promoter sequence from
the A. fumigatus heat shock protein-encoding gene, hspA, into the plasmid pCR-HygR (29). Then
promoter replacement transformation repair templates for cyp51A, cyp51B, and abcC were created by
PCR using primers (Table S2) which ampliﬁed both the hygromycin resistance cassette and the hspA
promoter from the plasmid pJMR2, while also introducing approximately 40 bases of homology targeting
sequences immediately upstream and downstream of the start codon for the respective gene of interest.
PCR products were subsequently puriﬁed using the Gene Clean II kit (MP Biomedicals). Cas9-RNP
complexes targeting sequences immediately upstream of the open reading frame of each gene of
interest were assembled as previously described (29).
Assessment of cyp51A, cyp51B, and abcC expression by RT-qPCR. For assessment of expression
in clinical isolates, conidia from each isolate were allowed to germinate overnight in Aspergillus minimal
medium incubated at 37°C on an orbital shaker at 250 rpm. For assessment of expression in constitutive
overexpression strains constructed in the akuBKU80 background, conidia from each isolate were allowed
to germinate overnight in Aspergillusminimal medium incubated at 37°C on an orbital shaker at 250 rpm
and then transferred to fresh Aspergillus minimal medium either with voriconazole at 0.125 mg/liter
(treated) or without voriconazole (untreated) for an additional 6 h at 37°C on an orbital shaker at 250
rpm. Then RNA was extracted from mature hyphae following liquid nitrogen crush as previously
described (35). The RevertAid RT kit (Thermo Scientiﬁc) was utilized to synthesize cDNA. PCR master mix
and SYBR were utilized to amplify A. fumigatus cyp51A, cyp51B, and abcC from cDNA by PCR per the
manufacturer’s instructions. Table S2 lists the gene-speciﬁc primers used for PCR. Conditions used for
PCR were as follows: AmpliTaq Gold activation at 95°C for 10 min, 40 cycles of denaturation at 95°C for
15 s, and annealing/extension at 60°C. The dissociation curve and threshold cycle (CT) was determined
using the CFX96 real-time PCR system (Bio-Rad). Changes in gene expression among isolates were then
calculated using the 2ΔΔCT method. All experiments were performed in triplicate from biological
triplicates. As previously described, ΔCT values were used to calculate the standard error (35). Statistical
analysis was performed using unpaired, two-tailed, Student’s t test in Prism 8 for Mac OS by GraphPad
Software Inc. with signiﬁcance set at 0.05 and degrees of freedom equal to 10.
Construction of allele replacement repair templates and Cas9-RNP for the cyp51A locus. The
plasmid pCyp51A-HygR was created by cloning the proximal 1.5 kb of promoter sequence and open
reading frame of the wild-type cyp51A allele from the genomic reference strain Af293, upstream of the
hygromycin resistance cassette in the plasmid pCR-HygR, and then cloning the proximal 1.5 kb of the
wild-type cyp51A terminator downstream of the hygromycin resistance cassette (29). Then, the cyp51AWT
transformation repair template was created by PCR using primers which ampliﬁed the wild-type cyp51A
allele (including 500 bases of promoter sequence), the hygromycin resistance cassette, and 500 bases of
the cyp51A terminator. Cas9-RNP complexes targeting sequences immediately upstream and approxi-
mately 500 bases downstream of the open reading frame of cyp51A were assembled as previously
described (29). Target-speciﬁc guide sequences are listed in Table S2.
Construction of allele replacement repair templates and Cas9-RNP for the hmg1 locus. Two-
component repair templates consisting of a split hygromycin resistance marker (hphR) and hmg1 alleles
of interest were prepared by PCR. Brieﬂy, hmg1 alleles of interest including the open reading frame and
approximately 500 downstream bases were ampliﬁed by PCR from DI15-98 (S305P), DI15-100 (I412S),
DI15-105 (F262del), and akuBKU80 (wild-type control) using a 3= primer which introduced the terminal 80
bases with homology to the 3= end of the hphR hygromycin B resistance gene open reading frame. A
partial hygromycin B resistance cassette, including the gdpA promoter and a truncated hphR gene
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lacking the terminal 40 bases, was then ampliﬁed by PCR from the pUCGH plasmid using primers that
introduced approximately 70 bases of homology with the downstream region of hmg1. Primers used are
listed in Table S2. PCR products were subsequently puriﬁed using the Gene Clean II kit (MP Biomedicals).
Cas9-RNP complexes targeting sequences immediately upstream and approximately 500 bases down-
stream of the open reading frame of hmg1 were assembled as previously described (29). Target-speciﬁc
guide sequences are listed in Table S2.
Aspergillus protoplast transformations. Transformation of A. fumigatus protoplasts was performed
as previously described with minor modiﬁcations (29). Approximately 2 g of each portion of applicable
transformation repair templates was then mixed with 200 l of protoplasts, 26.5 l of Cas9-RNP com-
plexes, and 25 l of polyethylene glycol (PEG)-CaCl2 buffer (60% [wt/vol] PEG 3350, 50 mM CaCl2·H2O,
450 mM Tris-HCl, pH 7.5) as previously described. Following an incubation on ice for approximately 1 h,
1.25 ml PEG-CaCl2 was added and the mixture was incubated for an additional 20 min at room
temperature. The mixture was then diluted to a total volume of 3 ml with STC buffer (1.2 M sorbitol,
7.55 mM CaCl2·H2O, 10 mM Tris-HCl, pH 7.5) and plated on SMM agar plates. Plates were then incubated
overnight prior to being overlaid with SMM top agar (GMM supplemented with 1.2 M sorbitol and 0.7%
[wt/vol] agar) supplemented with hygromycin (ﬁnal concentration of 150 g/ml), and the plates were
incubated at 37°C for 3 days. Transformants were isolated to separate plates containing selective agar,
genomic DNA was extracted, and successful CRISPR-Cas9 editing was conﬁrmed by PCR screens using
gene-speciﬁc primers and Sanger sequencing.
Clinical antifungal susceptibility testing. Susceptibilities for amphotericin B, voriconazole, isavu-
conazole, itraconazole, and posaconazole were determined for all isolates in accordance with CLSI
M38-A2 methodology utilizing broth microdilution in RPMI (31). Each antifungal was obtained from the
appropriate manufacturer. All agents were suspended in dimethyl sulfoxide (DMSO) for preparation of
stock solutions.
Comprehensive sterol proﬁling. Fresh conidial suspensions of each strain to be studied were
prepared in saline with Tween 80 from Aspergillus minimal medium agar plates. Conidia were grown in
25 ml RPMI supplemented with 0.2% glucose buffered to pH 7.0 with MOPS for 24 h in an orbital shaker
at 180 rpm and 35°C. Cells were then ﬂash-frozen using liquid nitrogen, dry weights were obtained, and
alcoholic KOH was utilized to extract nonsaponiﬁable lipids. A vacuum centrifuge (Heto) was then used
to dry samples, prior to derivatization by the addition of 200 l of anhydrous pyridine (Sigma), 100 l of
N,O-bis(trimethylsilyl)triﬂuoroacetamide (BSTFA)–10% trimethylsilyl (TMS) (Sigma), and 2 h of heating at
80°C. Gas chromatography-mass spectrometry (GC-MS) (Thermo 1300 GC coupled to a Thermo ISQ mass
spectrometer; Thermo Scientiﬁc) was then used to analyze and identify TMS-derivatized sterols. Known
standards were referenced for fragmentation spectra and retention times. Sterol proﬁles for each isolate
were then created using Xcalibur software (Thermo Scientiﬁc) to analyze GC-MS data (48). Statistical
analysis of both sterol proﬁles and total ergosterol per dry weight was performed using GraphPad Prism
7. In all cases, 6 independent biological replicates were measured and included in analysis, and two-tailed
unpaired t tests were performed in Prism 8 for Mac OS by GraphPad Software Inc. with signiﬁcance set
at 0.05 and degrees of freedom equal to 10.
Data availability.Whole-genome sequencing data ﬁles for the 26 Aspergillus fumigatus isolates have
been deposited in NCBI SRA under the accession number PRJNA491253.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
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